AssetMark Inc
CTMX icon

AssetMark Inc’s CytomX Therapeutics CTMX Stock Holding History

AssetMark Inc’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-44
Closed -$1K – 1450
2018
Q3 		$1K Hold
44
– – ﹤0.01% 1321
2018
Q2 		$1K Sell
44
-4
-8% -$102 ﹤0.01% 1325
2018
Q1 		$1K Hold
48
– – ﹤0.01% 1322
2017
Q4 		$1K Buy
+48
New +$995 ﹤0.01% 1578

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

AssetMark Inc's CTMX Position: Q4 2018 in Review

AssetMark Inc sold out of CytomX Therapeutics (CTMX) in Q4 2018, closing a stake of 44 shares — an estimated $1K sold.

AssetMark Inc first reported a position in CTMX in Q4 2017 and held it in 4 quarters. The position peaked at $1K in Q3 2018. 111 funds tracked by Wall St. Rank hold CTMX as of Q4 2018.

  • AssetMark Inc reported no remaining CytomX Therapeutics position as of Q4 2018 after selling out during the quarter.
  • AssetMark Inc sold 44 CytomX Therapeutics shares in Q4 2018, an estimated $1K.
  • AssetMark Inc first reported a position in CytomX Therapeutics in Q4 2017 and held it in 4 quarters.
  • AssetMark Inc's CytomX Therapeutics position peaked at $1K in Q3 2018.
  • 111 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2018.

Based on AssetMark Inc's 13F filing for Q4 2018, filed 13 Feb 2019.